<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Pharm Res</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Pharm Res</journal-id><journal-id journal-id-type="publisher-id">IJPR</journal-id><journal-title-group><journal-title>Iranian Journal of Pharmaceutical Research : IJPR</journal-title></journal-title-group><issn pub-type="ppub">1735-0328</issn><issn pub-type="epub">1726-6890</issn><publisher><publisher-name>Shaheed Beheshti University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25237332</article-id><article-id pub-id-type="pmc">4157012</article-id><article-id pub-id-type="publisher-id">ijpr-13-365</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Sang-hoon</given-names></name><xref ref-type="aff" rid="affa">a</xref><xref ref-type="aff" rid="affb">b</xref></contrib><contrib contrib-type="author"><name><surname>Chae</surname><given-names>Jung-woo</given-names></name><xref ref-type="aff" rid="affa">a</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Byung-jeong</given-names></name><xref ref-type="aff" rid="affa">a</xref></contrib><contrib contrib-type="author"><name><surname>Kwona</surname><given-names>Kwang-il</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="affa"><label>a</label><italic>College of Pharmacy, Chungnam National University, Korea.</italic></aff><aff id="affb"><label>b</label><italic>Medical Department, Novo Nordisk, Pharma Korea, Korea.</italic></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author: E-mail: kwon@cnu.ac.kr</corresp></author-notes><pub-date pub-type="ppub"><season>Spring</season><year>2014</year></pub-date><volume>13</volume><issue>2</issue><fpage>365</fpage><lpage>371</lpage><history><date date-type="received"><month>10</month><year>2012</year></date><date date-type="accepted"><month>5</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2014 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to allow the marketing of the test formulation. We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy male adult volunteers. This single-dose, randomized, double-blind, two-way crossover trial was conducted at Bestian Medical Center in Bucheon, Korea. In total, 40 male Korean volunteers were enrolled. The subjects were randomized to receive an FDC tablet containing the glimepiride/metformin (2/500 mg) test or reference formulation, and pharmacokinetic(PK) parameters were measured. After a 1-week washout period, the other formulation was administered and the PK parameters were measured again. The C<sub>max </sub>and AUC<sub>t </sub>were determined from blood samples obtained at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 h after drug administration. Bioequivalence was considered established if the 90% CIs of the geometric mean ratios(GMRs) of the test-to-reference formulations for C<sub>max </sub>and AUC<sub>t </sub>were within the predetermined regulatory range of 80-125%. In total, 40 healthy male subjects were enrolled and completed the study (mean [SD] age, 23.2[2.26]years[range, 19-30years];weight, 68.95[8.30]Kg[range, 52.0-87.0 Kg]; and height, 175.4[5.34] cm[range, 164-189 cm]). The GMRs(90% CI) of the glimepiride C<sub>max </sub>and AUC<sub>t </sub>were 1.006(0.947-1.069) and 1.010(0.953-1.071), respectively. For metformin, the values were 1.019(0.959-1.083) and 1.035(0.989-1.084), respectively. The test and reference formulations had similar PK parameters. The test formulation of glimepiride/metformin (2/500 mg) FDC tablets met the Korean regulatory criteria for bioequivalence. </p></abstract><kwd-group><title>Key Words</title><kwd>Metformin</kwd><kwd>Glimepiride</kwd><kwd>Combination drug</kwd><kwd>Bioequivalence</kwd><kwd>Pharmacokinetic properties</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Type 2 diabetes mellitus (DM) is a complex disease characterized by a range of metabolic defects, imbalances, and abnormalities affecting multiple organ systems. Three key defects herald the onset of hyperglycemia and type 2 diabetes: (<xref rid="B1" ref-type="bibr">1</xref>) impaired insulin action/insulin resistance in muscle, liver, and adipose tissue;(<xref rid="B2" ref-type="bibr">2</xref>) elevated prandial and postprandial hepatic glucose production, resulting, in part, from defects in glucagon regulation; and (<xref rid="B3" ref-type="bibr">3</xref>) diminished insulin secretion, resulting from defects in &#x003b2; cell function and mass (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B6" ref-type="bibr">6</xref>).Various medications have been approved for the treatment of type 2 D Min many countries. Combination treatments decrease the risk of medication non-compliance and have cost-saving effects (<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>).The most common combination regimens are (I) a sulfonylurea with metformin or a thiazolidinedione (TZD) and (II) metformin with a TZD (<xref rid="B9" ref-type="bibr">9</xref>). Metformin with a sulfonylurea causes greater reductions in HbA1c than either drug alone (<xref rid="B10" ref-type="bibr">10</xref>-<xref rid="B12" ref-type="bibr">12</xref>).</p><p>Glimepiride is an oral sulfonylurea antihyperglycemic agent. The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic &#x003b2; cells. Extrapancreatic effects may also play a role (<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B15" ref-type="bibr">15</xref>).Glimepiride is indicated for the treatment of type 2 DM at are recommended dosage of 18 mg/day for adults and is typically administered with other antihyperglycemic agents such as metformin or TZDs to provide adequate glycemic control (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B16" ref-type="bibr">16</xref>).</p><p>Metformin, a biguanide glucose-lowering agent, is commonly used to manage type 2 DM(<xref rid="B16" ref-type="bibr">16</xref>). Monotherapy with metformin is used as an adjunct to diet to manage type 2 DM in patients whose hyperglycemia cannot be controlled by diet alone (<xref rid="B17" ref-type="bibr">17</xref>).Metformin may also be used in combination with other antidiabetic agents in patients with type 2 DM who do not achieve adequate glycemic control with a sulfonylurea agent alone (<xref rid="B18" ref-type="bibr">18</xref>). The glucose-lowering effect of metformin is primarily the result of reduced hepatic glucose output, through the inhibition of gluconeogenesis and glycogenolysis (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>The sulfonylurea glimepiride might offer some advantages as a component of a fixed-dose combination(FDC) tablet with metformin due to its more prominent extrapancreatic activity and more favorable safety profile, compared with other sulfonylureas (<xref rid="B20" ref-type="bibr">20</xref>-<xref rid="B23" ref-type="bibr">23</xref>).The combination of glimepiride and metformin was approved by the US Food and Drug Administration in 1999.</p><p>The present bioequivalence study was designed to provide data to submit to regulatory authorities to allow marketing of the test formulation, which is the first generic glimepiride/metformin (2/500 mg) FDC tablet formulation approved in Korea. In this study, we compared the pharmacokinetic (PK) properties, safety profiles, and relative bioavailability of the generic (test) and brand(reference) glimepiride/metformin FDC tablets in healthy male Korean volunteers. </p></sec><sec><title>Experimental</title><p>
<italic>Subjects</italic>
</p><p>In total, 40 healthy Korean male volunteers participated. The subjects ranged in age from 19-30 years (mean SD, 23.2 2.26 years) and weighed between 52 and 87 Kg (mean SD, 68.958.29Kg). The demographic characteristics of the subjects are summarized in <xref ref-type="table" rid="T1">Table 1</xref>.All laboratory tests were performed at the Department of Laboratory Medicine, Bestian Medical Center(BMC, Bucheon, Korea), which has been accredited by the Korean Association of Quality Assurance for Clinical Laboratories.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of the 40 healthy Korean male subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Characteristic</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Mean</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>SD</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Median</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Range</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age(years)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">23.2</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">23.0</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">19-30</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Body weight(Kg)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">68.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.3</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">67.5</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">52-87</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Height(cm)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">175.4</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">5.3</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">174.0</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">164-189</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOO(%)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">100.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">8.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">99.0</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">80-120</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AST(U/L)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">22.1</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">4.7</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">17-32</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALT(U/L)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">21.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">7.2</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">20.5</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">11-41</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALP(U/L)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">245.1</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">45.2</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">245.5</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">161-359</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Albumin(g/dL)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">4.7</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">4.8</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">4.1-5.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total bilirubin(mg/ dL)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.5-1.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BUN(mg/dL)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">12.2</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">3.4</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">12.1</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">5.6-22.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCr(mg/dL)</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td style=" color:#000000;" align="center" valign="middle" rowspan="1" colspan="1">0.5-1.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CLcr(mL/min)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8-2.1</td></tr></tbody></table><table-wrap-foot><p>DOO Density of obesity, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ALP Alkaline phosphatase, BUN Blood urea nitrogen, SCr Serum creatinine, CLcr Creatinine clearance</p></table-wrap-foot></table-wrap><p>No subject had any significant cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, or hematological disorder, as determined by medical history and physical examinations; the latter included assessments of the subjects&#x02019; vital signs and clinical laboratory values(hematology, blood chemistry, and urinalysis). Furthermore, each subject was physically normal and had no previous history of significant illness or hypersensitivity to any drug. Finally, the subjects were asked to refrain from taking alcohol, caffeine, and any other drugs for at least 1week before and throughout the study period.</p><p>The study protocol was approved by the Institutional Review Board of BMC. All procedures were performed according to Good Clinical Practice guidelines and the Declaration of Helsinki for biomedical research (<xref rid="B24" ref-type="bibr">24</xref>) involving human subjects. All participants provided written informed consent to join the study before the screening test for eligibility.</p><p>
<italic>Study design and materials</italic>
</p><p>This bioequivalence study was conducted as a randomized, single-dose, two-period, two-sequence, crossover study. There were two treatment periods separated by a 1week washout period, which was more than five times the half-life, as determined in previous studies (<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>). A table of random numbers was used to assign subjects in a 1:1 ratio to receive the test drug or reference drug. All subjects fasted for at least 10h before administration. The study drug was given with 240 mL of water, and all subjects abstained from food until 4 h after dosing. After a washout period of 7 days, the same procedure was repeated with the other formulation. Dietary, smoking, and drug-herbal product restrictions were maintained throughout the study period. </p><p>
<italic>Blood sampling</italic>
</p><p>Blood samples for PK analyses were collected before and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 h after drug administration. They were drawn through an indwelling intravenous catheter placed in the forearm vein and transferred to a heparinized tube. After the first 1 mL of blood was discarded, a 9 mL sample was collected. Next, the cannula was flushed with 1 mL of normal saline to prevent clotting. Following centrifugation (3,000<italic>x g</italic>, 10min, 4 &#x000b0;C), plasma samples were transferred to microcentrifuge tubes and immediately stored at -70 &#x000b0;C until analysis. After a washout period of 7 days, the study was repeated in the same manner to complete the crossover design.</p><p>
<italic>Measurement of plasma glimepiride and metformin</italic>
</p><p>All plasma samples were handled and analyzed by BIOSUNTEK Laboratory Co., <italic>Ltd.</italic>(Sungnam, Korea) using validated bio analytical methods (<xref rid="B27" ref-type="bibr">27</xref>-<xref rid="B29" ref-type="bibr">29</xref>). Plasma concentrations of glimepiride and metformin were determined using validated high-performance liquid chromatography (HPLC,1200 series; Agilent Technologies, Inc., Santa Clara, CA, USA) coupled with Triple Quad LC/MS/MS(Agilent Technologies, Inc.). A Cap cell PAK C<sub>18</sub>UG80 (3.0 &#x000d7; 35 mm, 5 &#x000b5;m) column was obtained from Shiseido Co., <italic>Ltd.</italic>(Tokyo, Japan). Briefly, 200 &#x000b5;L of plasma was spiked with the internal standard (glipizide). Liquid-liquid extraction was done using 0.2% formic acid in acetonitrile for glimepiride and metformin. The mobile phase consisted of a mixture of methanol and 20 mM ammonium formate (80:20, v/v). The flow rate of the mobile phase was 0.4 mL/min and the injection volume was 10 &#x000b5;L. Glimepiride, metformin, and glipizide (Sigma-Aldrich, St. Louis, MO, USA) were detected by MS with an electrospray ionization interface, operating under positive selected reaction monitoring MS/MS conditions at the following mass transitions: 491.3&#x02192;352 <italic>m/z</italic> for glimepiride, 130.1&#x02192;71.1 <italic>m/z</italic> for metformin, and 446.2&#x02192;321.2 <italic>m/z</italic> for glipizide. <xref ref-type="fig" rid="F1">Figure 1</xref> shows structural representations of metformin, glimepiride, and glipizide.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Structural representation of metformin, glimepiride and glipizide</p></caption><graphic xlink:href="ijpr-13-365-g001"/></fig><p>For the quantification of glimepiride, the method had a linear quantifiable range of 2400 ng/mL and a &#x003b3;<sup>2</sup> of 0.997. The lower limit of quantitation(LLOQ) was 2 ng/mL. The intraday precision ranged from 3.31-8.27%, while the inter day precision ranged from 0.41-5.55%. The intraday accuracy was 102.6-103.6% while the inter day accuracy was 102.0-103.6%. The analyte was stable in human plasma following three freeze-thaw cycles, in plasma after storage for 6 h at room temperature, in stock solution after storage for 6 h at room temperature, and in the HPLC auto sampler after storage for 24 h.</p><p>For the quantification of metformin, the method had a linear quantifiable range of 5-2000 ng/mL and a &#x003b3;<sup>2</sup> of 0.998. The LLOQ was 5 ng/mL. The intraday precision ranged from 0.96-2.18%, while the inter day precision ranged from 3.26-9.77%. The intraday accuracy was 88.9-96.7% while the inter day accuracy was 98.2-100.2%. The analyte was stable in human plasma following three freeze-thaw cycles, in plasma after storage for 6 h at room temperature, in stock solution after storage for 6 h at room temperature, and in the HPLC auto sampler after storage for 24 h.</p><p>
<italic>PK analysis</italic>
</p><p>Changes in the plasma concentrations of glimepiride and metformin in each subject were analyzed using non-compartmental PK models and individual PK parameters were assessed using the BA-CALC program(KFDA, 2008, 1.0.0, Korea).PK parameters included the area under the plasma concentration-versus-time curve from 0 h to the last measurable concentration (AUC<sub>t</sub>), which was calculated using the linear trapezoidal rule, maximum plasma concentration (C<sub>max</sub>),and time required to reach the maximum plasma concentration (T<sub>max</sub>).The terminal elimination rate constant(&#x003bb;<sub>Z</sub>) was estimated using linear regression of the log-linear decline of individual plasma concentration-time data. The individual t<sub>&#x000bd;</sub>was calculated for each subject as ln2/&#x003bb;<sub>Z</sub>. AUC<sub>&#x0221e;</sub> was calculated as AUC<sub>t</sub>+ C<sub>last</sub>/&#x003bb;<sub>Z</sub>, where C<sub>last</sub> was the last measurable concentration (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>
<italic>Statistical analyses</italic>
</p><p>The demographic characteristics of the enrolled subjects were summarized using descriptive statistics. We used a sample size of 40, as required by the Korean Food and Drug Administration, because of the potential for dropouts during the study. Statistical analysis was performed using the K-BE test program(KFDA, 2007, 1.1.0, Korea).The GMRs of the test and reference values for AUC<sub>t</sub> and C<sub>max</sub> were calculated. The formulations were assumed bioequivalent if the 90% CIs for the GMRs of the test formulation to the reference formulation were from 0.8 to 1.25.</p></sec><sec><title>Results and Discussion</title><p>In total, 40 adult Korean male volunteers participated in this bioequivalence study. Physical examinations conducted before starting the study indicated that the subjects were healthy. There were no dropouts during the study period. No clinical AEs were reported.</p><p>
<xref ref-type="fig" rid="F2">Figure 2</xref> shows the mean &#x000b1; SD plasma concentration-time profiles of glimepiride and metformin after administration of two formulations of a glimepiride/metformin (2/500 mg) FDC tablet, and <xref ref-type="table" rid="T2">Table 2</xref> shows the values of the PK parameters for the test and reference formulations. The formulations had very similar AUC<sub>t</sub> and C<sub>max</sub> values. <xref ref-type="table" rid="T3">Table 3</xref> shows the GMRs of the reference and test drugs. The GMRs (90% CIs) of C<sub>max</sub> and AUC<sub>t </sub>for glimepiride and metformin ranged from 0.8 to 1.25. This meets the Korean regulatory criteria for bioequivalence.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Pharmacokinetic parameters following administration of the test and reference formulations of glimepiride/metformin 2/500 mg FDC tablet, in fasting, healthy male subjects(n=40)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="3" rowspan="1">(<bold>A) </bold><bold>Non-compartmental </bold><bold>Analysis of Glimepiride</bold><hr/></th></tr><tr><th align="center" valign="middle" rowspan="2" colspan="1">
<bold>Pharmacokinetic Results</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Test</bold>
<hr/>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Reference</bold>
<hr/>
</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Mean(SD)(CV%)</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean(SD)(CV%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AUC<sub>t</sub>, ng&#x02219;h/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">634.0(253.5)(40.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">625.0(253.9)(40.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">C<sub>max</sub>, ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">144.0(49.8)(34.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">143.3(51.3)(35.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">t<sub>&#x000bd;</sub>, h</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0(2.0)(68.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9(1.9)(65.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">T<sub>max</sub>, h<xref ref-type="table-fn" rid="TFN1">&#x02020;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">2.2(0.8,4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0(0.9,5.0)</td></tr><tr><td align="center" colspan="3" rowspan="1">
<bold>(B) </bold>
<bold>Non-compartmental</bold>
<bold> Analysis of Metformin</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="2" colspan="1">
<bold>Pharmacokinetic Results</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Test</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Reference</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mean(SD)(CV%)</td><td align="center" valign="middle" rowspan="1" colspan="1">Mean(SD)(CV%)</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>t</sub>, ng/h/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">6391.9(1605.5)(25.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">6162.2(1433.3)(23.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">C<sub>max</sub>, ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">1079.1(283.5)(26.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1062.4(274.9)(25.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">t<sub>&#x000bd;</sub>, h</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3(0.72)(21.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3(0.72)(21.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">T<sub>max</sub>, h<xref ref-type="table-fn" rid="TFN1">&#x02020;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">2.2(0.5, 4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5(0.8, 4)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>&#x02020;</label><p> Median(minimum, maximum).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Bioavailability of glimepiride and metformin after administration of test and reference drug of glimepiride/metformin 2/500 mg FDC tablet in healthy Korean volunteers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" valign="middle" colspan="2" rowspan="1">
<bold>Glimepiride</bold>
<hr/>
</th><th align="center" valign="middle" colspan="2" rowspan="1">
<bold>Metformin</bold>
<hr/>
</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Parameter</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Reference(n=20)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Test(n=20)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Reference(n=20)</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Test(n=20)</bold>
</th></tr><tr><th align="left" valign="middle" colspan="5" rowspan="1">
<bold>C</bold>
<sub>max</sub>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;GM<xref ref-type="table-fn" rid="TFN2">*</xref>(ng&#x02219;h/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">577.97</td><td align="center" valign="middle" rowspan="1" colspan="1">584.13</td><td align="center" valign="middle" rowspan="1" colspan="1">6105.93</td><td align="center" valign="middle" rowspan="1" colspan="1">6321.23</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;GMR<sup><xref ref-type="table-fn" rid="TFN3">&#x02020;</xref></sup>(90%CI)</td><td align="center" valign="middle" colspan="2" rowspan="1">1.01(0.96-1.07)</td><td align="center" valign="middle" colspan="2" rowspan="1">1.04(0.99-1.08)</td></tr><tr><td align="left" valign="middle" colspan="5" rowspan="1">
<bold>AUC</bold>
<sub>&#x0221e;</sub>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;GM<sup>&#x02020;</sup>(ng&#x02219;h/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">138.86</td><td align="center" valign="middle" rowspan="1" colspan="1">139.73</td><td align="center" valign="middle" rowspan="1" colspan="1">1054.26</td><td align="center" valign="middle" rowspan="1" colspan="1">1074.53</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;GMR<xref ref-type="table-fn" rid="TFN2">*</xref>(90%CI)</td><td align="center" valign="middle" colspan="2" rowspan="1">1.01(0.95-1.07)</td><td align="center" valign="middle" colspan="2" rowspan="1">1.02(0.96-1.08)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>*</label><p> Geometric mean </p></fn><fn id="TFN3"><label>&#x02020;</label><p> Geometric mean ratio</p></fn></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p>Mean(SD) plasma concentration-time profiles of glimepiride and metformin after administration 2 formulations of a glimepiride/metformin 2/500 mg FDC tablet</p></caption><graphic xlink:href="ijpr-13-365-g002"/></fig><p>The results of the current study indicate that a generic formulation of glimepiride/metformin (2/500 mg)FDC tablet met the regulatory requirements for assuming bioequivalence to the reference formulation, as established by the Korean Food and Drug Administration.</p></sec></body><back><ack><title>Acknoledgments</title><p>PhD Kwon was responsible for the study conception and design, and writing and revising of the manuscript. All authors agree with the contents of this manuscript, and the corresponding author made the final decision for submission. Jung, Chae and Song contributed to design and data analysis. Jung contributed to literature search, figure creation, and manuscript writing. Authors Chae and Kwon finally reviewed the manuscript. </p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Bonadonna</surname><given-names>RC</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name></person-group><article-title>Pathogenesis of NIDDM: a balanced overview</article-title><source> Diabetes Care</source><year>1992</year><volume>15</volume><fpage>318</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">1532777</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>BJ</given-names></name><name><surname>Haeften</surname><given-names>TW</given-names></name></person-group><article-title>Type 2 diabetes: principles of pathogenesis and therapy</article-title><source> Lancet</source><year>2005</year><volume>365</volume><fpage>1333</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">15823385</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritsche</surname><given-names>L</given-names></name><name><surname>Weigert</surname><given-names>C</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><name><surname>Lehmann</surname><given-names>R</given-names></name></person-group><article-title>How insulin receptor substrate proteins regulate the metabolic capacity of the liver implications for health and disease</article-title><source> Curr.Med. Chem</source><year>2008</year><volume>15</volume><fpage>1316</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">18537611</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>SE</given-names></name></person-group><article-title>The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of Type 2 diabetes</article-title><source> Diabetologia</source><year>2003</year><volume>46</volume><fpage>3</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">12637977</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornholm</surname><given-names>M</given-names></name><name><surname>Zierath</surname><given-names>JR</given-names></name></person-group><article-title>Insulin signal transduction in human skeletal muscle: identifying the defects in type II diabetes</article-title><source> Biochem. Soc. Trans</source><year>2005</year><volume>33</volume><fpage>354</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">15787605</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name></person-group><article-title>Current views on type 2 diabetes</article-title><source> J. Endocrinol</source><year>2010</year><volume>204</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">19770178</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G</surname><given-names>Schernthaner</given-names></name></person-group><article-title>Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care</article-title><source> Diabet. Med</source><year>2010</year><volume>27</volume><fpage>739</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">20636953</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Kamalakkannan</surname><given-names>G</given-names></name><name><surname>Parkar</surname><given-names>S</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group><article-title>Fixed-dose combinations improve medication compliance: a meta-analysis</article-title><source> Am. J. Med</source><year>2007</year><volume>120</volume><fpage>713</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">17679131</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name></person-group><article-title>Oral antihyperglycemic therapy for type 2 diabetes: scientific review</article-title><source> JAMA</source><year>2002</year><volume>287</volume><fpage>360</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">11790216</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosi</surname><given-names>F</given-names></name><name><surname>Muggeo</surname><given-names>M</given-names></name><name><surname>Brun</surname><given-names>E</given-names></name><name><surname>Spiazzi</surname><given-names>G</given-names></name><name><surname>Perobelli</surname><given-names>L</given-names></name><name><surname>Zanolin</surname><given-names>E</given-names></name><name><surname>Gori</surname><given-names>M</given-names></name><name><surname>Coppini</surname><given-names>A</given-names></name><name><surname>Moghetti</surname><given-names>P</given-names></name></person-group><article-title>Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study</article-title><source> Metab.Clin. Exp</source><year>2003</year><volume>52</volume><fpage>862</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12870162</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>AJ</given-names></name><name><surname>Larsen</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>SH</given-names></name><name><surname>Piper</surname><given-names>BA</given-names></name><name><surname>Henry</surname><given-names>D</given-names></name></person-group><article-title>Glyburide/Metformin Initial Therapy Study Group. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes</article-title><source>Diabetes Obes. Metab</source><year>2002</year><volume>4</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">12047399</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>AJ</given-names></name><name><surname>Donovan</surname><given-names>DS Jr</given-names></name><name><surname>Dandona</surname><given-names>P</given-names></name><name><surname>Bruce</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name></person-group><article-title>Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes</article-title><source> J. Clin. Endocrinol. Metab</source><year>2003</year><volume>88</volume><fpage>3598</fpage><lpage>3604</lpage><pub-id pub-id-type="pmid">12915642</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>W</given-names></name><name><surname>Muller</surname><given-names>G</given-names></name><name><surname>Geisen</surname><given-names>K</given-names></name></person-group><article-title>Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta cells</article-title><source> Horm. Metab. Res</source><year>1996</year><volume>28</volume><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">8911984</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badian</surname><given-names>M</given-names></name><name><surname>Korn</surname><given-names>A</given-names></name><name><surname>Lehr</surname><given-names>KH</given-names></name><name><surname>Malerczyk</surname><given-names>V</given-names></name><name><surname>Waldhausl</surname><given-names>W</given-names></name></person-group><article-title>Absolute bioavailability of glimepiride (Amaryl) after oral administration</article-title><source> Drug Metabol. Drug Interact</source><year>1994</year><volume>11</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">12369756</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benet</surname><given-names>LZ</given-names></name></person-group><article-title>Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System</article-title><source> Basic Clin. Pharmacol. Toxicol</source><year>2010</year><volume>106</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">20002064</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>GK</given-names></name><name><surname>Livak</surname><given-names>KG</given-names></name></person-group><source>AHFS drug information</source><year>2002</year><publisher-loc>Washinton DC</publisher-loc><publisher-name>ASPH</publisher-name><fpage>3052</fpage><lpage>3061</lpage></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moses</surname><given-names>R</given-names></name><name><surname>Slobodnjuk</surname><given-names>R</given-names></name><name><surname>Boyages</surname><given-names>S</given-names></name><name><surname>Colagiuri</surname><given-names>S</given-names></name><name><surname>Kidson</surname><given-names>W</given-names></name><name><surname>Carter</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>T</given-names></name><name><surname>Moffitt</surname><given-names>P</given-names></name><name><surname>Hopkins</surname><given-names>H</given-names></name></person-group><article-title>Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes</article-title><source> Diabetes Care</source><year>1999</year><volume>22</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">10333912</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>KI</given-names></name></person-group><source>Clinical Drug Therapy of Disease</source><year>2003</year><edition>2nd ed</edition><publisher-loc>Seoul</publisher-loc><publisher-name>Shinil</publisher-name><fpage>433</fpage><lpage>437</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Goodman</surname><given-names>AM</given-names></name></person-group><article-title>For The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus</article-title><source> N. Engl. J. Med</source><year>1995</year><volume>333</volume><fpage>541</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">7623902</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Patterson</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name></person-group><source>Bioequivalence and Statistics in Clinical Pharmacology</source><year>2005</year><publisher-loc>Boca Raton </publisher-loc><publisher-name>Chapman &#x00026; Hall/CRC</publisher-name></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Frid</surname><given-names>A</given-names></name><name><surname>Hermansen</surname><given-names>K</given-names></name><name><surname>Shah</surname><given-names>NS</given-names></name><name><surname>Tankova</surname><given-names>T</given-names></name><name><surname>Mitha</surname><given-names>IH</given-names></name><name><surname>Zdravkovic</surname><given-names>M</given-names></name><name><surname>During</surname><given-names>M</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name></person-group><article-title>Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD(Liraglutide Effect and Action in Diabetes)-2 study</article-title><source> Diabetes Care</source><year>2009</year><volume>32</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18931095</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>U</given-names></name><name><surname>Pal</surname><given-names>TK</given-names></name></person-group><article-title>Formulation and in-vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release</article-title><source>Drug Dev. Ind. Pharm</source><year>2008</year><volume>34</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">18363146</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defang</surname><given-names>O</given-names></name><name><surname>Shufang</surname><given-names>N</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>G</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Weisan</surname><given-names>P</given-names></name></person-group><article-title>In-vitro and in-vivo evaluation of two extended release preparations of combination metformin and glipizide</article-title><source> Drug Dev. Ind. Pharm</source><year>2005</year><volume>31</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">16207615</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><article-title>[The Helsinki Declaration]</article-title><source>Assist Inferm. Ric</source><year>2010</year><volume>29</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">20514811</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Weng</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name></person-group><article-title>Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy chinese male volunteers</article-title><source> Clin. Ther</source><year>2010</year><volume>32</volume><fpage>959</fpage><lpage>995</lpage></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al</surname><given-names>Hawari S</given-names></name><name><surname>AlGaai</surname><given-names>E</given-names></name><name><surname>Yusuf</surname><given-names>A</given-names></name><name><surname>Abdelgaleel</surname><given-names>A</given-names></name><name><surname>Hammami</surname><given-names>MM</given-names></name></person-group><article-title>Bioequivalence study of two metformin formulations</article-title><source> Arzneimittelforschung</source><year>2007</year><volume>57</volume><fpage>192</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">17515289</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>P</given-names></name><name><surname>Bhaumik</surname><given-names>U</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Sarkar</surname><given-names>AK</given-names></name><name><surname>Chatterjee</surname><given-names>B</given-names></name><name><surname>Bose</surname><given-names>A</given-names></name><name><surname>Pal</surname><given-names>TK</given-names></name></person-group><article-title>LC&#x02013;MS&#x02013;MS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study</article-title><source> Chromatographia</source><year>2009</year><volume>69</volume><fpage>1243</fpage><lpage>1250</lpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>YK</given-names></name><name><surname>Maeng</surname><given-names>JE</given-names></name><name><surname>Hwang</surname><given-names>HR</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name></person-group><article-title>Determination of glimepiride in human plasma using semi-microbore high performance liquid chromatography with column-switching</article-title><source> J. Chromatogr. B</source><year>2004</year><volume>810</volume><fpage>143</fpage><lpage>149</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najiba</surname><given-names>N</given-names></name><name><surname>Idkaideka</surname><given-names>N</given-names></name><name><surname>Beshtawia</surname><given-names>M</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><name><surname>Admour</surname><given-names>I</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>Zaman</surname><given-names>Q</given-names></name><name><surname>Dham</surname><given-names>R</given-names></name></person-group><article-title>Bioequivalence Evaluation of Two Brands of Metformin 500 mg Tablets (Dialon1 &#x00026; Glucophage1) &#x02013; in Healthy Human Volunteers</article-title><source> Biopharm. Drug Dispos</source><year>2002</year><volume>23</volume><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">12355581</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gabrielsson</surname><given-names>J</given-names></name><name><surname>Weiner</surname><given-names>D</given-names></name></person-group><source>Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications</source><year>2007</year><edition>4th(eds.)</edition><publisher-loc> Stockholm Sweden</publisher-loc><publisher-name>Swedish Pharmaceutical Press </publisher-name><fpage>1</fpage><lpage>4</lpage></element-citation></ref></ref-list></back></article>